
Daniel Heng, MD, MPH, FRCPC, discusses LITESPARK-011 and LITESPARK-012 data defining belzutifan's role in second-line and later advanced RCC.

Daniel Heng, MD, MPH, FRCPC, discusses LITESPARK-011 and LITESPARK-012 data defining belzutifan's role in second-line and later advanced RCC.

Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.

Daniel Heng, MD, discusses the FDA approval of belzutifan plus lenvatinib in RCC, managing hypoxia and anemia, and how it may affect treatment sequencing.